Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference
10 juin 2016 07h30 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., June 10, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at the Jefferies 2016 Healthcare Conference
02 juin 2016 08h00 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., June 02, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation)
25 mai 2016 16h30 HE
|
Melinta Therapeutics, Inc.
Solithromycin safety and efficacy further validated by Toyama (FUJIFILM) All efficacy outcome measures favored solithromycin Management to host Q&A webcast and conference call tomorrow at 8:00...
Cempra to Present Solithromycin IV Data at ATS 2016
12 mai 2016 16h05 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., May 12, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports First Quarter 2016 Financial Results and Provides Corporate Update
01 mai 2016 17h05 HE
|
Melinta Therapeutics, Inc.
NDA submissions completed for solithromycin intravenous and oral capsule formulations in the treatment of community-acquired pneumonia Management to host webcast and conference call tomorrow at...
Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
01 mai 2016 17h00 HE
|
Melinta Therapeutics, Inc.
Solithromycin is designated by FDA as a Qualified Infectious Disease Product FDA has granted Priority Review and Fast Track designation for solithromycin IV and capsules for the treatment of CABP ...
Cempra to Report First Quarter 2016 Financial Results
25 avr. 2016 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at the Needham and Company 15th Annual Healthcare Conference
06 avr. 2016 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Participate in Nature's Webcast on Combating Antibiotic Resistance on March 9
08 mars 2016 16h10 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., March 08, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Authorized to Receive Funds From BARDA for a Phase 2/3 Clinical Trial of Solithromycin in Pediatric Patients
07 mars 2016 07h00 HE
|
Melinta Therapeutics, Inc.
Phase 2/3 Pivotal Trial Will Test Intravenous, Oral Capsule and Oral Suspension Formulations of Solithromycin in Pediatric Patients From Age 2 Months to 17 Years Cempra to Receive $25.5...